...Welcome back, everyone. Welcome to the 2025 RBC Global Healthcare conference. My name is Greg Renza, one of the biotech equity research analysts here at RBC. And we're very pleased to have Nurix Therapeutics, a team and a company we know well. Joining us from the company is Chief Business Officer, Jason Kantor; as well as Chief Financial Officer, Hans Van Houte. Guys, it's great to see you. Always a lot of activity and interest in Nurix, and we're in an interesting time with the company, with data unveiling, with maturity of obviously your oncology platform but also emergence into I&I. So maybe for those who who aren't familiar with Nurix, I'll just have you give a brief overview of the company along with the targeted protein degradation. Hans Van Houte ...